SOBER Study Overview 2023-06-01

SOCIAL BENEFITS OF RECOVERY (SOBER) STUDY
2023-06-01
Program Summary
This application is titled “Social Benefits of Recovery” (SOBER Study), a prospective, observational study that
will examine and compare productivity and other recovery-oriented outcomes in two parallel groups who are
participating in treatment for their opioid use disorder (OUD): those who receive neurostimulation from NET
Recovery Corp’s (NRC) investigational NET Device, and those who do not receive neurostimulation from the
NET Device.
The SOBER Study provides innovative treatment for 500 persons with OUD who wish to be abstinent without
medication, provides a one-year snapshot of person-based, recovery-oriented social outcomes for a sizable
(1,000 person) OUD population, and demonstrates and enables a sustainable model for aggregating and
analyzing social measures from multiple disparate Kentucky agencies.
The SOBER Study will take data from Kentucky Center for Statistics (KYstats), Cabinet for Health and Family
Services (CHFS), Medicaid, and Kentucky All Schedule Prescription Electronic Reporting (KASPER). Data will be
collected over 12 months, including wages, unemployment claims, educational engagement, use of
medications for OUD (MOUD), arrest, incarceration, overdose, and death. The non-NET group will be
statistically matched to the NET group on relevant characteristics. Analyses will examine trends in outcomes
over time, and whether NET outcomes are comparable (non-inferior) to non-NET outcomes.
History
NRC has a long history researching NET in Kentucky, starting with two treatment projects in Powell County in
2006, and two KRADD-sponsored treatment projects conducted in Hazard in 2007. Open label clinical trials for
several hundred patients from 60 Kentucky counties were conducted at Isaiah House, and 5 Kentucky residents
were filmed during treatment as part of the 2020 international award winning documentary “The Final Fix”
narrated by Ewan McGregor (https://www.amazon.com/Final-Fix-Ewan-McGregor/dp/B086Z6JK29), as filmed
in 8 Kentucky counties.
Innovation
FDA-approved OUD medications are effective for many but not all persons, and there is a major unmet need
for OUD treatment alternatives for persons who wish to be opioid abstinent without MOUD. The NET Device
expands treatment options, especially as a non-opioid approach with lower abuse potential.
Copyright © 2023, NET Recovery Corp | CONFIDENTIAL & PROPRIETARY | NETrecovery.net Page 1 of 13
Funding
Permissible Uses
The SOBER Study provides abstinence-based detoxification and treatment at residential treatment facilities for
persons with OUD and assesses long term social benefits within the context of opioid abatement research.
Under Section 5(a) of KRS 15.291, settlement funds may be used for “reimbursement for … any portion of
the cost related to outpatient and residential treatment services, including: … (c) abstinence-based
treatment.”
Under Section 5(b) of KRS 15.291, settlement funds may be used for any project which (1) supports
intervention, treatment, and recovery services provided to persons with OUD, (2) supports detoxification
services, and/or (29) is deemed appropriate for opioid-abatement purposes by the commission.
Under Exhibit E, Schedule B (“Approved Uses”), Part 2, Section L (“Research”) of the Janssen Settlement
Agreement, funding may be used to “support opioid abatement research.”
Funding Goal & Partners

The NRC team is requesting National Opioid Settlement funding from multiple Kentucky counties to be solely
used for the purposes of planning and conducting the SOBER Study.
Project Description
The project comprises pre-treatment, treatment, and post-treatment phases.
Pre-Treatment Phase
During the Pre-Treatment Phase, the team will develop a research protocol that describes the background,
rationale, objectives, design, methodology, statistical considerations, and organization of the SOBER Study, as
per ICH Good Clinical Practice guidelines. The team will obtain documentation and agreements from partners
Wayne State University (principal investigator), University of Louisville (co-principal investigator and Clinical
Trials Unit services), Isaiah House (clinical sites), UTHealth Houston (biostatistics), and BlueVector (study
monitor) including letters of support, clinical study support agreements, reliance agreements, data sharing
agreements, HIPAA Business Associate Agreements, and statements of work, as appropriate. The research
protocol and agreements will be submitted to an Institutional Review Board (IRB) for approval and the study
will be registered on clinicaltrials.gov. The team will develop recruitment materials, training materials, and data
collection, storage, validation, and processing instruments.
In addition, the team will develop a sustainable model for aggregating and analyzing health, treatment, wage,
justice, workforce, and educational participation data from KYstats, CHFS, Medicaid, and KASPER using KYstats
as the primary party in data sharing agreements, the collection and analysis party for individualized data, and
the provider of aggregated outcomes data to the Study. See Methods of Data Collections for details.
NRC will hire additional research assistants (“RA”s) and will provide training to researchers and study site
personnel as performed for the currently ongoing randomized controlled trial of NET taking place in Kentucky.
All RAs will undergo CITI training for responsible conduct of research (RCR), human subjects research, and
information privacy and security.
Site Protocol Training will be delivered once at each study site during the pre-treatment phase and will include:
• Study protocol overview

• Investigational device overview
• Roles and responsibilities (Site, RA, PI, Sponsor)
• Points of contact
Research Assistant Protocol Training will be delivered (Lexington) during the pre-treatment phase with all
research assistants in attendance and will include:
• Study protocol overview and detail

• Investigational device overview
• Roles and responsibilities (Site, RA, PI, Sponsor)
• Research ethics review
• Eligibility review
• Informed Consent review and practice
• MS Surface tablet review and practice
• Case Report Form (CRF) review and practice
• SandCloud (electronic data capture system) tool review and practice
• Adverse Event review
• HR topics
Research Assistant Device Training will be delivered (Lexington) during the pre-treatment phase with all
research assistants in attendance and will include:
• Research vs therapeutic roles

• Neuromodulation overview
• OUD and poly-substance overview
• Investigational device operation
• Clinical application (NET Vue) review and practice
• Withdrawal severity scale review and practice
• Device operations practice session
• Troubleshooting
• Assessment test
Treatment Phase
During the Treatment Phase, potential participants will be screened, undergo eligibility evaluation, and enrolled
at one of several participating Isaiah House residential treatment facilities. Research assistants will administer
and obtain informed consent and HIPAA authorization. Eligibility will be determined by one of the principal
investigators or qualified designates. RAs will attach the NET Device, train the participant in self-administration,
and collect daily case report form information regarding treatment acceptability and tolerability, efficacy, and
safety during the stimulation period (up to seven days). The participant may elect to stay at Isaiah House
beyond the stimulation period or engage in any other wrap around services as they find appropriate.
This Treatment Phase will replicate procedures from the ongoing randomized controlled trial of the NET Device.
The Wayne State University IRB has already approved these treatment procedures, and the entire team
(Sponsor, Principal Investigator, IRB, Study Monitor, Study Coordinator, CTO, Isaiah House staff, RAs, and
Biostatistician) has extensive experience in delivering this rigorous and safe treatment protocol. Thus, virtually
all onsite issues have been addressed in the ongoing NET Device trial and implementation of SOBER will be
smooth. Furthermore, SOBER will be all active (no sham) treatment, so benefits will be greater than in the
ongoing trial.
Study participants could experience clinical deterioration during the opioid discontinuation process.
Participants may discontinue device use at any time and for any reason. Participants may request standard-of-
care OUD treatment appropriate to their clinical condition (including MOUD) at any time. Upon delivery of such
standard-of-care (including MOUD), use of the device will be discontinued. Seeking or receiving standard-of-
care is not considered dropout and does not change the participant’s status in the study.
Onsite Observation Training including observation, feedback, correction, and affirmation in the live study
environment will be delivered once during the treatment phase with all initial RAs at all study sites and will
include:
• Participant interactions
• Site staff interactions
• Ethical research behaviors
• Protocol adherence
• Investigational device use
• SandCloud and NET Vue application use
In addition, RA Protocol Training, RA Device Training, and Onsite Observation Training will be delivered as
required for all new RAs onboarded during the treatment phase.
Post-Treatment Phase
During the Post-Treatment Phase, identifying data for all NET treatment participants will be delivered to
KYstats. In collaboration with the biostatistician, KYstats will mine their census data and identify a matching
comparator group of persons seeking residential care for OUD who did not receive NET. KYstats will collect
individualized data for both groups on an annual or quarterly basis (as available) from agency partners under
existing and study-specific data sharing agreements. KYstats will perform statistical analyses as determined by
the biostatistician and provide aggregated results and certain de-identified individualized data to the Study
team. The Study expects to produce an interim report and a final report.
Project Mission
The SOBER Study will provide treatment for 500 persons with OUD who wish to be abstinent without MOUD.
The innovative neurostimulation treatment is to be provided within the controlled environment of a research
study directed by experienced investigators from Wayne State University and University of Louisville and
conducted at multiple Kentucky residential treatment facilities.
The study will measure and comparatively assess productivity and other social outcomes for both the NET-
treated population and a matched control group using data and statistical analysis from KYstats. The study
allows county and health officials to assess person-based, recovery-oriented measures in addition to the more
frequently studied outcomes such as death and overdose, in the context of a sustainable model. In addition,
the study allows county and health officials to observe the integration of an innovative treatment for OUD
within the established patient treatment pathway.
Goals
a) Provide treatment for 500 persons with OUD who wish to be abstinent without medication.
b) Measure and comparatively assess productivity and other social outcomes for both the treated population
and a matched control group, augmenting the more frequently studied abstinence outcomes with person-
based, recovery-oriented measures.
c) Demonstrate and enable a sustainable model for aggregating social outcomes from multiple disparate
Kentucky agencies.
d) Demonstrate integration of an innovative treatment for OUD within the established patient treatment
pathway.
Measurable Objectives
1. The main independent variable will be receipt of one or more hours of NET treatment during short-term
residential treatment at a participating inpatient residential treatment facility.
2. The primary outcomes will be wages and workforce participation rates at baseline, 3, 6, 9, and 12 months
after admission to treatment.
3. Secondary outcomes will be unemployment claims, educational engagement (GED, career, technical),
arrest, incarceration, overdose, and death.
4. Additional covariates include age, sex, race/ethnicity, MOUD utilization, and education level at baseline.
5. The Incremental cost-effectiveness ratio (ICER) integrated evidence rating, combining ratings for
comparative clinical effectiveness and for comparative value, will be calculated.
Project Rationale
Addiction remains one of the most critical public health and safety issues facing the Commonwealth of
Kentucky1. Ambitious implementation studies in addiction research address the current opioid crisis with a
focus on reducing the risk of overdose and death2. While these are grave outcomes, a larger segment of the
OUD population suffers from less catastrophic, though serious, negative consequences outside of the
immediate realm of drug use in domains such as productivity, health, and criminality3. The estimated
productivity loss from substance use disorder in the United States is over $100 billion annually, mainly due to
labor participation costs, participation in drug abuse treatment, incarceration, and premature death4,5. Adults
who have a current OUD are significantly more likely to be unemployed and make less income compared with
those with past OUD or those without lifetime OUD6. The proposed SOBER Study will provide innovative
abstinence-based NET treatment to 500 persons entering short-term residential treatment for OUD, will
compare productivity and other social benefit outcomes over 12 months for persons receiving NET treatment
versus persons not receiving NET, will demonstrate and enable a sustainable model for aggregation and
analysis of social measures from multiple disparate Kentucky agencies, and will demonstrate integration of an
innovative treatment for OUD within the established patient treatment pathways presently existing in
Kentucky.
Gaps in Service
FDA-approved OUD medications are effective for many but not all persons who seek OUD treatment, and there
is a major unmet need for treatment alternatives for persons who wish to be opioid abstinent without
medication. Presently, OUD treatment engagement levels are unacceptably low from a public health
perspective – only about 20% of persons with OUD in the US are in treatment7. Many individuals are interested
in effective non-medication treatment options, but these are presently limited. This could lead many OUD
patients to not seek treatment or to drop out of treatment. Put another way, we need to “meet patients where
they are” to get them into treatment and to stay in treatment. The FDA has stated the importance of expanding
treatment options, especially non-opioid approaches that have lower abuse potential.
The use of the NET Device for treatment in this disease space is not intended to replace existing approved
treatments, but rather to provide a safe and effective alternative for patients and clinicians who wish to choose
from available options to optimize personal, clinical, and public health outcomes.
1
2021 Combined Annual Report, Kentucky Office of Drug Control Policy & Kentucky Agency for Substance Abuse Policy
2
Chandler R. K. et al (2020). Addressing opioid overdose deaths: The vision for the HEALing communities study. Drug and Alcohol
Dependence, 217. 10.1016/j.drugalcdep.2020.108329
3
Tiffany S. T. et al (2012). Beyond drug use: A systematic consideration of other outcomes in evaluations of treatments for
substance use disorders. Addiction, 107(4), 709-718. 10.1111/j.1360-0443.2011.03581.x
4
https://recoverycentersofamerica.com/resource/economic-cost-of-substance-abuse-disorder-in-united-states-2019/
5
https://obamawhitehouse.archives.gov/ondcp/ondcp-fact-sheets/how-illicit-drug-use-affects-business-and-the-economy
6
Rhee T. G., & Rosenheck R. A. (2019). Association of current and past opioid use disorders with health-related quality of life and
employment among US adults. Drug and Alcohol Dependence, 199, 122–128. 10.1016/j.drugalcdep.2019.03.004
7
SAMHSA, National Findings Report, 2018
Innovation
NeuroElectric Therapy (NET) is a promising non-pharmacological treatment for persons with OUD that is
currently undergoing rigorous clinical efficacy evaluation in Kentucky (Contemporary Clinical Trials
Communications, https://doi.org/10.1016/j.conctc.2022.101018). The study seeks to determine whether use of
the NET Device reduces opioid withdrawal symptom severity and increases illicit opioid abstinence without use
of MOUD. If the study is successful, NET could represent an innovative primary treatment for the underserved
population of persons who wish to be abstinent without MOUD.
NET has been studied extensively, albeit open-label and without control, over several decades, and exclusively
in the inpatient setting, as a possible monotherapy for medication-free detoxification from chronic substance
use (Patterson et al. 1975, 1993, 1996). The safe clinical use of the NET Device has been demonstrated and the
clinical benefit indicated in two observational uncontrolled one-arm pilot studies, in which a total of 424
participants completed NET treatment. The investigations took place at seven residential rehabilitation
facilities in the UK and one in Kentucky (Isaiah House). The principal investigator for both studies was Dr. Phyllis
Platt, Spalding University (Louisville, KY), Chair of the School of Social Work.
The benefit, as indicated in the pilot studies and as being assessed in the current randomized controlled trial, is
that use of the NET Device as treatment for OUD is associated with low rates of relapse to opioids or other
drugs of abuse without use of prescribed medication.
In a systematic literature review of 38 medication arms from 26 studies, NET was non-inferior to methadone,
buprenorphine, clonidine and lofexidine for suppressing residential opioid detoxification-related withdrawal
symptoms and craving (Greenwald et al., unpublished data).
The NET Device is an investigational medical device that received CE-Mark as a Class IIa active device with
minimal adverse effects. The device has been determined to be a Non-Significant Risk (NSR) device by the
Wayne State University IRB (IRB-21-07-3820). The NET Device delivers neurostimulation via surface electrode
pads placed trans-cranially (bilaterally) on the mastoid processes. The device produces low-amperage
alternating current waveforms at controlled frequencies and pulse widths (using proprietary algorithms).
Results from observational uncontrolled one-arm pilot studies in Europe and the USA indicate that NET
monotherapy, i.e., without MOUD, can rapidly decrease opioid detoxification-related craving and withdrawal
symptom elevations. Specifically, treatment completers (68–84% of participants in two unpublished reports)
reported significant symptom reduction during the first 15–20 minutes of stimulation that was sustained
throughout residential treatment (which ranged from 4–14 days in different studies). After inpatient NET
treatment, completers who could be followed on an outpatient basis were drug tested for use of opioids,
MOUD, or other drugs of abuse (49 participants followed out of 116 participants). Approximately 85% of the
followed completers tested negative for illicit opioids, methadone, and buprenorphine, and 98% tested
negative for cocaine and methamphetamines. Completers were defined as participants who remained in
treatment for 4 or more days or departed earlier with a craving score of 0.
Target Service Population
The SOBER Study will recruit to the NET treatment cohort from among the approximately 400 monthly persons
entering OUD treatment at Isaiah House for short term treatment (typically 28 days). Eligibility criteria for
receiving NET treatment include diagnosis of mild, moderate, or severe OUD (DSM-5), presenting with Clinical
Opiate Withdrawal Scale (COWS) score of moderate or above, adult in general good health, and not pregnant.
There is no treatment exclusion criterion related to cocaine or methamphetamine use. Participants will receive
standard of care at Isaiah House.
Ethnicity, race, and sex/gender will not exclude participants. The study will attempt to recruit a participant
sample that is approximately 65% male and 35% female, with a racial/ethnic distribution that is approximately
80% white, 15% African American, and 5% Other (including Hispanic).
Identity of Underserved Population

This project provides innovative primary treatment for the underserved population of persons with OUD who
wish to be abstinent from opioids without medication.
Risks, barriers
There is no FDA-approved treatment for persons who wish to be abstinent without medication. Of the 2 to 4
million Americans who receive OUD treatment annually, less than half will successfully complete their
treatment episode (Frimpong, Guerrero, Kong, and Kim, 2016) and for those who do successfully complete,
non-abstinence is as high as 71% post-treatment (Laudet and White, 2008).
Engaging with the population

Isaiah House (Willisburg, KY) admits approximately 400 persons per month across multiple facilities for
residential treatment for OUD and/or Substance Use Disorder (SUD). Open label studies and the current
randomized controlled trial at Isaiah House have found that a significant portion of the admitted population
expresses interest in abstinence without medication as a long-term outcome. The SOBER Study will recruit from
this population to provide treatment with the investigational NET Device.
Service Delivery Description
Patients admitted to participating residential treatment facilities (listed below) with a diagnosis of OUD will be
recruited to participate in the study and potentially receive NET treatment. RAs will administer and obtain
informed consent and HIPAA authorization. Eligibility will be determined by one of the principal investigators or
qualified designates. Prior to initiation of NET Device stimulation, withdrawal severity will be assessed using the
COWS score, and craving will be assessed using the Opioid Craving Scale (OCS, McHugh 2014, 2021). RAs will
attach the NET Device, train the participant in self-administration, and collect daily case report form
information regarding treatment acceptability and tolerability, efficacy, and safety during the stimulation
period (up to 7 days). NET stimulation duration is from 1-hour to 7 days, self-administered, as the participant
perceives benefit. The participant may elect to continue to stay at Isaiah House beyond the stimulation period
or engage in any other wrap around services as they find appropriate.
Study participants could experience clinical deterioration during the opioid discontinuation process.
Participants may discontinue device use at any time and for any reason. Participants may request standard-of-
care OUD treatment appropriate to their clinical condition (including MOUD) at any time. Upon delivery of such
standard-of-care, use of the device will be discontinued. Seeking or receiving standard-of-care is not considered
dropout and does not change the participant’s status in the study.
Physical Study Locations (Isaiah House Facilities)

Isaiah House Main Willisburg KY 92 beds Men 2.5 per week
Patricia’s Place Willisburg KY 20 beds Men 1 per week
Women’s Center Versailles KY 30 beds Women 1.5 per week
Shelley Center Harrodsburg KY 96 beds Women 2 per week
Lisa Walker Center Harrodsburg KY 16 beds Women 0.5 per week
Jake Kuertz Center Chaplin KY 24 beds Men 1 per week
Greg Bowen Center Chaplin KY 24 beds Men 0.5 per week
Louisville Oliva Center Louisville KY 72 beds Men 4 per week
Timeline
Protocol, Partners, IRB Treat 500 participants
Collect quarterly data
Prelim Rpt Final Rpt
Pre-Treatment Phase Treatment Phase Post-Treatment Phase
2023 2024 2025 2026

Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Data Source
Data Item Data Source Year Collected
Consent, HIPAA Auth Research Staff 2024Q1 to 2024Q4
NET Stimulation Data Research Staff 2024Q1 to 2024Q4
Social Outcomes KYstats 2024Q2 to 2026Q1
Interim and Final Report NET Recovery 2025Q2, 2026Q2
Methods of Data Collections
KYstats will collect individualized data for both groups (receiving and not receiving NET treatment) on an annual
or quarterly basis as available from multiple agency partners under existing and study-specific data sharing
agreements. Data will include health, treatment, wage, justice, workforce, and educational participation data.
KYstats will perform statistical analyses as determined by the biostatistician and provide aggregated results and
certain de-identified individualized data to the Study team.
A goal of this Study is to develop and enable a sustainable model for aggregation and analysis of person-
centered recovery-oriented data regarding the Kentucky OUD population from multiple state agencies (e.g.,
KYstats, CHFS, Medicaid, and KASPER) using KYstats as the primary party in data sharing agreements, the
collection and analysis party for individualized data, and the provider of aggregated outcomes data. It is
anticipated that NRC will develop and deliver to KYstats automation software and processes sufficient to
generate the study analytic outputs. KYstats will be trained in use of the automation software and processes
such that they can independently generate aggregated analytic outputs for the study using the individualized
data collected for this study.
Collaboration and Coordination
The SOBER Study team comprises NET Recovery Corp, Wayne State University, University of Louisville, Isaiah
House, Kentucky Center for Statistics, UTHealth Houston, and BlueVector.
The principal investigator is Dr. Mark Greenwald, PhD; Professor (tenured) and Gertrude Levin Endowed Chair
in Addiction and Pain Biology in the Dept. of Psychiatry and Behavioral Neurosciences; and Adjunct Professor,
Dept. of Pharmacy Practice, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State
University (Detroit MI); Professor with Continuing Tenure, Dept. of Psychiatry and Behavioral Neurosciences,
Wayne State University School of Medicine. Dr. Greenwald has published multiple landmark papers on the
pharmacology, safety, and efficacy of buprenorphine and on the neurobiology of addiction, and he serves as
principal investigator for the current randomized control trial for the NET Device currently underway in
Kentucky.
The co-principal investigator is Dr. Chris Stewart, MD, CGP, DFAPA, Associate Professor with the University of
Louisville (Louisville KY), Department of Psychiatry and Behavioral Sciences, and Director of the Addictions
Program at the UofL Physicians Outpatient Center.
The University of Louisville Clinical Trials Unit will also be providing medical staff to provide eligibility
determinations for prospective participants, and to monitor adverse events, in the NET treatment cohort.
During the treatment phase, potential participants will be screened, undergo evaluation, and enrolled at one of
several participating Isaiah House residential treatment facilities. Isaiah House is a well-established Kentucky-
based treatment center offering short- and long-term residential stays, an intensive outpatient program,
medication-assisted treatment, transitional living, and job skills training. Their staff include experienced,
licensed therapists, a medical team with advanced practice registered nurses, registered nurses, medical
assistants, state certified adult peer support specialists and target case managers. Isaiah House has experience
working with NET and with NRC’s research staff, as they are the study site for the currently running randomized
controlled trial of NET and were the USA study site for the open-label NET study conducted by Spalding
University (Louisville, KY).
Eight separate Isaiah House facilities will participate: 5 for males-only and 3 for females-only. Senior
management, therapists and nursing staff provide services across all facilities. All core services (group hours,
structured activities, chores, meals), even though individualized, are driven by the same policies and
procedures at all locations. The scheduling of those services can vary slightly by location. Other than individual
variation in clinical approach the over-all service provision is the same for females and males. All staff are under
common management. The program administrator and clinical director act across the organization with site
supervisors and lead clinical staff present at each location. The admissions process, medical and clinical
assessments occur separately for males and females at their respective facilities.
The Kentucky Center for Statistics (KYstats, Frankfort KY) collects, analyzes, and maintains data regarding
education and workforce efforts from multiple agencies in the Commonwealth. In addition, KYstats will enter
into data sharing agreements with CHFS, Medicaid, and KASPAR for individualized data. KYstats will provide an
initial data set to validate the effect size, collaborate with the biostatistician to mine their census data and
identify a matching comparator group of persons who did not receive NET, collect data for both groups on a
quarterly or annual basis, perform statistical analyses as determined by the biostatistician and provide
aggregated results and certain de-identified individualized data to the Study team.
The biostatistician is Dr. Samiran Ghosh, PhD, Professor and Vice Chair, Biostatistics and Data Science,
UTHealth, Houston (Houston, TX). Dr. Ghosh has published multiple papers on the design and analysis of non-
inferiority trials, and he coauthored (with Dr. Greenwald and Joe Winston, NRC) the study design paper for the
ongoing randomized controlled trial of the NET Device.
The study monitor functions are being supplied by Cheryl Lockett BSc (Hons) MSc MBA FICR FRSB CSci at
BlueVector (Edinburgh, UK), a life science consultancy which serves the medical device, pharmaceutical and
biotechnology industries. Ms. Lockett has experience executing and providing training for clinical trial programs
at multiple medical device and pharmaceutical companies, and is the Study Monitor for the ongoing
randomized controlled trial of the NET Device.
Contact
For more information, please contact:
Jeff Lott
Director of Communications
NET Recovery
Jeff.Lott@NetRecovery.net

SOBER Study Overview 2023-06-01

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

SOBER Study Overview 2023-06-01

Uploaded by

Copyright:

Available Formats

SOCIAL BENEFITS OF RECOVERY (SOBER) STUDY

Funding Goal & Partners

• Study protocol overview

• Study protocol overview and detail

• Research vs therapeutic roles

Identity of Underserved Population

Engaging with the population

Physical Study Locations (Isaiah House Facilities)

2023 2024 2025 2026

You might also like